To be taken orally, preferably 15-30 minutes before meals and at bedtime.

Domperidone blocks dopamine D2 receptors primarily in the chemoreceptor trigger zone (CTZ) in the brain and in the gut, thereby reducing nausea and vomiting and promoting gastric emptying.

• •Known hypersensitivity to Domperidone or any component.
• •Patients with a prolactin-releasing pituitary tumour (prolactinoma).
• •Moderate to severe hepatic impairment.
• •Conditions where stimulation of gastrointestinal motility might be harmful (e.g., gastrointestinal haemorrhage, mechanical obstruction, perforation).
• •Concomitant use with potent CYP3A4 inhibitors (e.g., ketoconazole, erythromycin).
• •Patients with existing prolongation of cardiac conduction intervals, particularly QTc.

Store below 30°C in a dry place, away from light and moisture.

Symptoms include drowsiness, disorientation, extrapyramidal reactions. Management: symptomatic and supportive treatment, gastric lavage, activated charcoal.

Limited data in pregnancy; use only if potential benefit outweighs risk. Excreted in breast milk; advise caution/alternative feeding during lactation.